Bright minds biosciences initiates the breakthrough study: a phase 2 trial of bmb-101 in absence epilepsy and developmental epileptic encephalopathy

Bright minds biosciences announces phase 2 clinical trial to evaluate bmb-101 in a group of drug-resistant epilepsy disorders with high unmet needs bmb-101 is a novel highly selective 5-ht2c agonist. its g-protein biased agonism provides an improved mechanism of action for chronic dosing financial runway extending into 2026 enabling key data readout conference call & kol event – will be held as a webcast on september 25th at 10:00 et  new york , sept.
DRUG Ratings Summary
DRUG Quant Ranking